Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Receivables - Accured (2016 - 2025)

Historic Revenue - Other for Celldex Therapeutics (CLDX) over the last 4 years, with Q1 2013 value amounting to $2.3 million.

  • Celldex Therapeutics' Revenue - Other fell 42.66% to $2.3 million in Q1 2013 from the same period last year, while for Dec 2013 it was $2.3 million, marking a year-over-year decrease of 7833.67%. This contributed to the annual value of $2.3 million for FY2013, which is 7833.87% down from last year.
  • Per Celldex Therapeutics' latest filing, its Receivables - Accured stood at $6.0 million for Q3 2025, which was up 1320.75% from $6.2 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Receivables - Accured peaked at $6.2 million during Q2 2025, and registered a low of $300000.0 during Q2 2021.
  • Moreover, its 5-year median value for Receivables - Accured was $1.3 million (2021), whereas its average is $2.6 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Revenue - Other skyrocketed by 12352.94% in 2011, and later plummeted by 631.49% in 2012.
  • Celldex Therapeutics' Revenue - Other (Quarter) stood at $1.7 million in 2010, then surged by 42.82% to $2.4 million in 2011, then skyrocketed by 50.59% to $3.6 million in 2012, then crashed by 34.27% to $2.3 million in 2013.
  • Its last three reported values are $2.3 million in Q1 2013, $3.6 million for Q4 2012, and $3.0 million during Q3 2012.